Population pharmacokinetic modelling, Monte Carlo simulation and semi-mechanistic pharmacodynamic modelling are all tools that can be applied to personalize gentamicin therapy. This review summarizes and evaluates literature knowledge on the population pharmacokinetics and pharmacodynamics of gentamicin and identifies areas where further research is required to successfully individualize gentamicin therapy using modelling and simulation techniques. Thirty-five studies have developed a population pharmacokinetic model of gentamicin and 15 studies have made dosing recommendations based on Monte Carlo simulation. Variability in gentamicin clearance was most commonly related to renal function in adults and body weight and age in paediatrics. Nine studies have related aminoglycoside exposure indices to clinical outcomes. Most commonly, efficacy has been linked to a C max /MIC !7-10 and a AUC 24 /MIC !70-100. No study to date has shown a relationship between predicted achievement of exposure targets and actual clinical success. Five studies have developed a semimechanistic pharmacokinetic/pharmacodynamic model to predict bacteria killing and regrowth following gentamicin exposure and one study has developed a deterministic model of aminoglycoside nephrotoxicity. More complex semi-mechanistic models are required that consider the immune response, use of multiple antibiotics, the severity of illness, and both efficacy and toxicity. As our understanding grows, dosing of gentamicin based on sound pharmacokinetic/pharmacodynamic principles should be applied more commonly in clinical practice.
Introduction
Gentamicin is an aminoglycoside antibiotic widely used for the treatment of Gram-negative and some Gram-positive bacterial infections. 1 Gentamicin exhibits concentration-dependent bactericidal killing, whereby higher drug exposure is linked to a greater rate and extent of bacterial eradication [2] [3] [4] and a post-antibiotic effect, which may result in a delayed regrowth of surviving bacteria following antibiotic exposure. 5 Bacteria are, however, capable of developing adaptive resistance to gentamicin, such that initially susceptible bacteria acquire a temporary resistance within a treatment period. Adaptive resistance may increase and become prolonged with continued exposure. 6 Use of gentamicin is associated with significant nephrotoxicity and ototoxicity, thought to be a result of drug accumulation in the cells of the proximal renal tubule and inner ear. 7, 8 Nephrotoxicity and ototoxicity have been associated with long therapy duration, 9 high drug exposure 10 and multiple daily dosing regimens. 11 Gentamicin mainly distributes into extracellular water with minimal binding to plasma proteins and low intracellular penetration. 12 It is predominantly excreted from the body unchanged by glomerular filtration and exhibits a higher degree of tubular reabsorption compared with other aminoglycoside antibiotics, which tends to make it more nephrotoxic. 13, 14 Gentamicin displays large between-subject pharmacokinetic variability 15 with several factors reported to influence drug exposure including a patient's weight, age and renal function and critical illness. [16] [17] [18] Tailoring the dosage of gentamicin to an individual's requirements can be difficult due to its narrow therapeutic window, large betweensubject pharmacokinetic variability and the serious clinical consequences of under-and over-exposure.
A population pharmacokinetic model characterizing typical population parameter values, between-subject and betweenoccasion pharmacokinetic variability, and covariate influences on pharmacokinetics can be used to assist with drug dosage decisions. 19 Such a model may be applied in a Monte Carlo simulation study to obtain the probability of achieving desired target exposures under different dosing regimens 20 or linked to a semimechanistic pharmacodynamic model to predict treatment outcomes under different dosing scenarios. Semi-mechanistic models may be based on time-kill curve experiments done in vitro or on pre-clinical in vivo studies where bacteria killing is tested against a V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com single antibiotic or combinations of antibiotics, across different static or dynamic systems and/or with repeated dosing over time.
This review summarizes and evaluates literature knowledge on the population pharmacokinetics and pharmacodynamics of gentamicin and identifies areas where further research is required to successfully individualize gentamicin therapy using modelling and simulation techniques. It focuses on four study types: (i) studies that have developed a population pharmacokinetic model of gentamicin; (ii) studies that have made dosage regimen recommendations based on a population model applied in Monte Carlo simulation; (iii) studies that examine the association between aminoglycoside exposure indices and clinical outcomes; and (iv) studies that have developed a semi-mechanistic pharmacokinetic/pharmacodynamic model of gentamicin to predict treatment outcomes.
Methods

Literature search and data extraction
A literature search was conducted in September 2016 using PubMed and EMBASE databases with a restriction on English language publications. The following search terms were used: (population pharmacokinetics* OR pharmacokinetics*) AND (population pharmacodynamics* OR pharmacodynamics*) AND (gentamicin* OR aminoglycosides*) AND (Monte Carlo simulation* OR simulation*) AND (Clinical outcomes* OR efficacy*). After removing duplicates, titles and abstracts of potentially relevant articles were screened for appropriateness. Full-text versions of apparently relevant articles were subsequently retrieved and reviewed to confirm eligibility. Key methodological features and results from relevant studies were extracted and summarized in tables. The range of typical pharmacokinetic parameter estimates of CL and volume of distribution across similar populations has been provided in the manuscript text. Parameters were standardized to a body weight of 70 kg so that values across studies performed in adult and paediatric patients could be compared. 21, 22 To achieve this, typical parameter values reported in each study were divided by median study weight multiplied by 70 kg. In situations where a one-compartment disposition model was employed, the term V d is used to symbolize a single volume of distribution. In situations where a multi-compartment disposition model was employed, the terms V c , V p and V p2 are used to symbolize the central and one and/or two peripheral volume of distribution compartment(s) respectively.
Results
Population pharmacokinetic models of gentamicin
Thirty-five studies describing the population pharmacokinetics of gentamicin were identified. The number of patients included in each study ranged from 5 to 1449 (median: 97), with 23 studies (66%) including >50 participants. Eighteen studies (51%) were prospective, 15 studies (43%) retrospective and 2 studies (6%) involved both prospective and retrospective data collection. Non-linear mixed-effects modelling techniques were used to develop the population pharmacokinetic model in 30 studies (86%), with NONMEM software most commonly utilized. The main study objectives were to estimate pharmacokinetic parameters, characterize covariate influences and predict drug exposure under different dosing regimens through Monte Carlo simulation. The pharmacokinetics of gentamicin were described using one-, two-and threecompartment disposition models in 20 (57%), 13 (37%) and 2 (6%) studies, respectively. Median (range) sampling time across studies was 2.0 h (0.02-321) after the end of infusion. Seventeen (49%) studies measured gentamicin concentration-time points on more than one occasion and three studies (9%) reported values for between-occasion variability in pharmacokinetic parameters. Diagnostic techniques to identify model improvement were applied in most studies and included examining the objective function value, performing visual predictive checks and generating goodness-of-fit plots. The final model was externally and internally validated in 6 (17%) and 11 (31%) studies, respectively. From 24 studies that reported residual unexplained variability, a combined residual error model was used in 10 studies (42%), a proportional error in 9 studies (38%) and an additive error in 5 studies (21%). Across the studies, proportional residual unexplained error ranged from 5% to 144% and additive error ranged from 0.02 to 0.76 mg/L.
Adults and the elderly
Fourteen studies were performed in adults. 16, 18, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] The key features of these studies are summarized in Table 1 The percentage of studies that tested and identified a particular covariate as significant is presented in Figure 1 (a and b) for gentamicin CL and volume of distribution, respectively. Renal function was the most common covariate to have an influence on the clearance of gentamicin. CL CR was positively related to gentamicin CL in 7 out of 10 studies (70%) that tested it; and serum creatinine was inversely related to gentamicin CL in 1 out of 5 studies (20%) that tested it. 24 Clearance of gentamicin was also greater during haemodialysis. 16, 26, 32, 34 28 Body size was the most common covariate to have an influence on gentamicin volume of distribution. Patient weight was positively related to volume of distribution in 9 out of 14 studies (71%) that tested it. Other size descriptors positively associated with gentamicin volume of distribution were BSA in oncology 23 and cystic fibrosis patients, 31 dosing weight (the lower value of either lean body weight or total body weight) in patients with varying renal function, 29 and lean body weight (LBW) in elderly patients. 28 The volume of distribution was higher in the critically ill 33 (V d 53.0 L/ 70 kg) and lower in anuric patients receiving haemodialysis 26 (V c 9.31 L/70 kg) compared with other adults with normal renal function (V d 19.6 L/70 kg). 25 
Paediatrics
Twenty-one studies were performed in paediatric patients. 17, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] The key features of these studies are summarized in Table 2 . One study included only children (>2 years of age), two studies involved Review The time when gentamicin concentrations were drawn was not specified but they were obtained on multiple occasions. 
Review
add (mg/L): 0.135 35, 54 and two included neonates with sepsis. 41, 49 The percentage of studies that tested and identified a particular covariate as significant is presented in Figure 1(c and d) for gentamicin CL and volume of distribution, respectively. The most common covariates identified as influencing gentamicin CL were patient body weight and age. Patient body weight was positively related to gentamicin CL in 15 out of 17 studies (88%) that tested it; and patient age was positively related to gentamicin CL in 14 out of 19 studies (74%) that tested it. Different descriptors were used for age across the studies. PNA 37, 39, 41, 46, 54 and gestational age (GA) 40, 42, 47, 49, 53 were incorporated in five different studies each. PNA and GA were both included in two studies, 17, 43 PNA and post-conception age or post-menstrual age was incorporated in two studies. 44, 52 Patient renal function (based on CL CR or serum creatinine measurement) was positively related to gentamicin CL in 6 out of 15 studies (40%) that tested it. The typical CL of gentamicin was higher in children (CL 7.21 L/h/70 kg) 35 Figure 1 . Percentage of population pharmacokinetic studies that tested and identified a particular covariate as having a significant influence on gentamicin clearance (a) and volume of distribution (b) in adults and on gentamicin clearance (c) and volume of distribution (d) in paediatrics. The fulllength bar represents the percentage of studies that tested a given covariate and the black shaded bar represents the percentage of studies in which a given covariate was identified as having significant influence on the named parameter. Fourteen studies were performed in adults and included patients from 14 to 97 years of age. Twenty-one studies were performed in paediatrics and included patients from 1 day to 15 years of age. Age, represents either post-natal age, gestational age or post-conception age; Apgar, an objective score of the condition of a baby after birth; base deficit, a decrease in the total concentration of bicarbonate in blood; BSA, body surface area; CL CR , creatinine clearance; ITU, treated in intensive therapy unit.
Body size was the most common covariate to have an influence on gentamicin volume of distribution. Patient weight had a positive relationship with volume of distribution in 13 out of 14 studies (93%) that tested it. Two out of six studies (33%) reported that age (GA) had an influence on volume of distribution, 17 54 and children (V c 17.8 L/70 kg) 35 with severe malnutrition have a lower volume of distribution than other infants (V c 24.5 L/70 kg). 38 
Dose recommendations based on Monte Carlo simulation and model predictions
Nineteen studies were identified that applied population pharmacokinetic models to make dosing recommendations ( Table 3 .
Adults and the elderly
Seven studies were performed in adults. 16, 25, 26, [32] [33] [34] 55 Four studies included patients undergoing haemodialysis, 16, 26, 32, 34 two studies involved patients with varying degrees of renal impairment 25, 33 and one study included elderly patients. 55 Studies in haemodialysis patients showed that pre-dialysis dosing is likely to be more effective and safer than post-dialysis dosing. In patients with normal renal function, a dose of 7 mg/kg/every 24 h (q24h) was deemed appropriate. However, in patients with renal impairment with a CL CR between 45 and 80 mL/min a dosing interval of 48 h was recommended. 25 In patients with a CL CR < 40 mL/min, extending the dosing interval even further was suggested. 25 In the critically ill (mean CL CR 48 mL/min), a dose of 7 mg/kg was deemed likely insufficient, suggesting the need to increase the dose in these patients; 33 however, the dosing interval associated with this dosage was never discussed. In three groups of elderly patients with a CL CR from 30 to 119 mL/min, a dosing regimen of 3 mg/kg/q24h resulted in the highest percentage of simulated subjects achieving the exposure target in all groups. 55 
Paediatrics
Twelve studies were performed in paediatric patients. 17, [37] [38] [39] 43, 44, 46, 50, 53, 54, 56, 57 Six studies simulated different dosing regimens of gentamicin in preterm and term neonates, 17, 39, 43, 46, 56, 57 two studies performed simulations in infants with a mean age of 5 months, 37, 38 two studies included neonates with hypoxic ischaemic encephalopathy 50, 53 one study involved neonates with different Apgar scores, 44 and one study included infants with severe malnutrition. 54 In premature neonates, increasing the dosing interval to 36-48 h was suggested to achieve desired exposure indices. 17, 43 A dose of 4 mg/kg/q24h and 4-5 mg/kg/q36-48h was recommended in term and preterm neonates, respectively. 17, 39, 43 Neonates with low Apgar scores had a reduced gentamicin CL, which may affect the dosing regimen. 44 A dose of 2.5 mg/kg/q12h, 3 mg/kg/q18h and 3.5 mg/kg/q24h was recommended in neonates with a post-conceptional age (PCA) >34 weeks and 5 min Apgar !7; PCA 34 weeks or 5 min Apgar <7; and PCA 34 weeks and 5 min Apgar <7, respectively. 44 In neonates with a GA of 36-40 weeks with hypoxic ischaemic encephalopathy, a dose regimen of 4-5 mg/kg/q36h was recommended over a dosing regimen every 24h; 50, 53 however, in neonates with a GA of 42 weeks a dosing regimen of 5 mg/kg/q24h was recommended. 53 In infants in intensive care with a mean age of 5 months a dosing regimen of 7-8 mg/kg/q24h was suggested. 37, 38 A dosing regimen of 7.5-15 mg/kg/q24h was recommended in infants with severe malnutrition with a median age of 20 months. 54 
Studies linking aminoglycoside exposure indices to clinical outcome
Since only one study was identified that specifically examined the link between gentamicin exposure indices and clinical outcomes, the search was extended to all studies involving aminoglycosides, and nine studies were subsequently found (see Table 4 ).
2-4,58-63
Seven studies were performed in adults with different conditions such as pneumonia, sepsis, intra-abdominal and lower respiratory tract infection. [2] [3] [4] [58] [59] [60] 63 One study included patients with a mean (range) age of 15 years (8-21 years) with cystic fibrosis 61 and one study involved neonates in intensive care. 62 Exposure indices evaluated across the studies were maximal C max , mean C max , AUIC (area under the curve over 24 h over actual inhibitory titres), first measured C max /MIC, second measured C max /MIC, AUC 24 /MIC, C max /MIC, adjusted free drug (f)C max /MIC and fAUC 24 /MIC. The target exposure aimed for in each study is displayed in Table 4 . The most common exposure indices linked to cure were C max /MIC and AUC 24 /MIC in adults. However, in younger patients [mean age (range) 15 years (8-21 years)] the best predictors of cure were fC max /MIC and fAUC 24 /MIC. 61 In neonates with a mean GA of 36 weeks, the AUC 24 /MIC ratio was not considered a significant predictor of gentamicin's effectiveness, suggesting that a high AUC 24 / MIC ratio can potentially increase the risk of toxicity. 62 Only one study included patients who received aminoglycosides across different dosing intervals. 59 However, this study did not evaluate whether the link between exposure indices and clinical outcome is schedule dependent. The highest percentage of positive clinical cure (!90%) was seen in 78 patients of whom 49 patients (63%) received aminoglycosides twice-daily for a median (range) of 11 days (8) (9) (10) (11) (12) (13) (14) and achieved a C max /MIC ! 12.5 and AUC 24 /MIC ! 175. 59 Toxicity was seen in 10% of patients treated for 12 days. 59 One study 63 evaluated the correlation between predicted antibiotic efficacy using a population pharmacokinetic model applied in Monte Carlo simulation and actual clinical success in patients with pneumonia who received b-lactams, fluoroquinolones and aminoglycosides. Pharmacokinetic/pharmacodynamic Review JAC amikacin (48) maximal (26) meropenem (8) ciprofloxacin (24) levofloxacin (39) gentamicin (6) tobramycin (14) amikacin (13) BD, twice-daily regimen; CV%, coefficient of variance; NR, not reported; GM, geometric mean aminoglycoside concentration; OD, once-daily regimen; SIT 2, 62 and none have tried to make a link with ototoxicity. The incidence of nephrotoxicity was not statistically significant in those patients who were successfully treated (patients who achieved a mean C max ! 6 mg/dL) in comparison with those in whom therapy failed (C max < 6 mg/dL). Semi-mechanistic pharmacokinetic/pharmacodynamic models of gentamicin Five studies [64] [65] [66] [67] [68] were identified that developed a semimechanistic pharmacokinetic/pharmacodynamic model of gentamicin based on in vitro time-kill experiments to describe the time course of bacterial kill and regrowth after gentamicin treatment (Table 5) .
Two studies 66, 67 performed static time-kill experiments to evaluate gentamicin concentrations ranging from 0.5 to 16 times the MIC against Staphylococcus aureus and Pseudomonas aeruginosa and from 1 to 32 times the MIC against P. aeruginosa. In the first study a dynamic hollow-fibre infection model 69 was also setup to evaluate different gentamicin dosing regimens (once daily dosing targeting a C max >24 mg/L and three times daily dosing targeting a C max >8 mg/L against S. aureus and P. aeruginosa).
66
Static time-kill curves revealed that gentamicin has different bactericidal effects against P. aeruginosa and S. aureus strains. Against P. aeruginosa, maximal killing occurred under all tested concentrations of gentamicin with a rapid decline in bacterial burden within 2 h of exposure. Gentamicin concentrations between 0.5 and 4 times the MIC showed a predominant bactericidal effect on S. aureus which did not increase further with higher concentrations. Microbiological response using the hollow-fibre model showed that against P. aeruginosa, no difference in bacteria killing activity for gentamicin was seen regardless of the dosing schedule. Against S. aureus, giving gentamicin every 8 h avoided regrowth and sustained bacterial suppression in contrast to a once-daily regimen. Based on these results the authors suggested that the well-accepted concentration-dependent bacterial activity of aminoglycosides may not be applicable for all bacteria. 66 In a second study, simulations were conducted using different C max /MIC targets for gentamicin at different dosing intervals: 67 a C max /MIC ratio of 4 at a dosing frequency of q8h, a C max /MIC ratio of 12 at a dosing frequency of q24h, a C max /MIC ratio of 36 at a dosing frequency of q24h, and a C max /MIC ratio of 30 at a dosing frequency of q12h. Bacterial regrowth over time emerged in almost all regimens simulated, except with a C max /MIC ratio of 30 at a dosing frequency of q12h, which seemed to suppress the development of true resistance. The investigators concluded that while a C max /MIC ratio is commonly believed to be the most important index for aminoglycoside efficacy, a dosage regimen that provides a lower C max /MIC ratio but a large AUC/MIC ratio (due to twice daily dosing) prevented the development of true resistance.
67
One criticism of the models used in the two above-described studies 66 ,67 is that they predict the continuous development of resistance, prohibiting bacteria from reverting to initial susceptibility when gentamicin exposure diminishes. In addition, the models do not consider the coexistence of sensitive and resting bacteria with different susceptibilities. 64, 65 Two studies 64, 68 evaluated different dosing regimens of gentamicin using a semi-mechanistic pharmacokinetic/pharmacodynamic model in preterm and term newborn infants 64 and patients with end-stage renal disease receiving haemodialysis. 68 A binding function 64 and an adaptive factor 68 were included in these models to characterize bacteria regrowth after initial decline of gentamicin concentrations. Static and dynamic time-kill experiments were performed to evaluate gentamicin concentrations ranging from 0.125 to 20 times the MIC against E. coli, 64 S. aureus (MSSA and MSSR) 68 and P. aeruginosa. 68 Extreme preterm newborns achieved lower peak concentrations of gentamicin than more mature neonates. A dose of 4 mg/kg/24h was the most effective in the term newborn infant. However, doses >4.5 mg/kg for the extended dose interval should be considered. Bacterial killing increased when the loading dose also increased, suggesting that a higher initial dose of gentamicin may be recommended to prevent the development of adaptive resistance. Considering toxicity for extreme preterm neonates, a dose of 6 mg/kg/q36h was suggested to be the highest dose still providing gentamicin concentrations <2 mg/L prior to redosing. None of the investigated dosing regimens achieved concentrations <1 mg/L within a 36 h dosing interval. 64 In patients with end-stage renal disease receiving haemodialysis two dosing regimens were evaluated: a post-dialysis regimen of 120 mg gentamicin at the end of infusion and a pre-dialysis regimen of 240 mg gentamicin 1 h before haemodialysis. 68 The authors suggested that although the majority of the patients (90%) under the post-dialysis dosing failed to achieve a C max !8 mg/L, this dosing regimen led to lower risk of toxicity with 80% of patients achieving a C min 2 mg/L in comparison to 25.3% under the post-dialysis regimen. In addition, the model-predicted bacteria counts at 24 h showed that both fAUC/MIC and fC max/ MIC have a high correlation with antibacterial effect of gentamicin against P. aeruginosa.
The same semi-mechanistic pharmacokinetic/pharmacodynamic model mentioned above 64 was used to assess simulated dosing regimens of six antibiotics including gentamicin and to evaluate the influence of altered simulation settings. 65 Simulations from the model showed that a gentamicin regimen of 4.5 mg/kg/q24h was associated with initial rapid bacterial killing within 4 h after initiation of therapy. However, bacterial regrowth close to the maximum achievable bacterial count in the system was predicted to occur 24 h after treatment. For gentamicin, fAUC/MIC was selected as the pharmacokinetic/pharmacodynamic index showing the highest correlation with antibacterial effect.
One study developed a deterministic model to describe aminoglycoside non-linear accumulation in the renal cortex, effect on renal cells and subsequent tubule-glomerular feedback and changes in serum creatinine. 70 Utilizing 49 observed serum creatinine concentrations from a group of eight patients treated for endocarditis, it showed that for the same daily dose, nephrotoxicity observed with a thrice-daily administration schedule appeared more rapidly, induces a greater decrease in renal function and is more prolonged compared with less frequent administration. Furthermore it appeared that time of day of administration may influence the incidence of aminoglycoside nephrotoxicity, with potentially less nephrotoxicity when gentamicin was administered at 1:30 p.m. 
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Adaptive resistance of gentamicin:
Discussion
This review summarizes current literature knowledge on the population pharmacokinetics and pharmacodynamics of gentamicin. Over 30 population pharmacokinetic and/or pharmacodynamic studies of gentamicin have now been performed; however, there are still patient groups that have not been widely characterized, including children, 35 elderly patients, 28 the critically ill and those receiving potential nephrotoxic medications such as immunosuppressant and chemotherapy agents. 23 In semi-mechanistic studies to date only P. aeruginosa, S. aureus and E. coli bacterial strains have been considered.
In population pharmacokinetic studies disposition of gentamicin has been described using one, two and three compartmental models. Model selection is likely dependent on the richness of the pharmacokinetic profiling performed. A multi-compartmental model which considers tissue distribution and accumulation may be more useful in predicting gentamicin efficacy and toxicity over time. 43 In adults, CL CR and serum creatinine were the most common covariates reported to influence gentamicin CL, reflecting the fact that gentamicin is predominantly renally eliminated. 18, 23, 25, 32 Body weight was the most common covariate reported to influence gentamicin volume of distribution, reflecting the fact larger individuals have more extracellular fluid for gentamicin to distribute into. Lean body weight as a size descriptor 71 was not commonly utilized in the studies, though it is advised in some dosing guidelines for obese individuals. 72 One study involving 2073 patients has shown that LBW is a better body size descriptor than both body weight and ideal body weight to describe volume of distribution of gentamicin in patients at different weight categories (from underweight to obese). 73 In paediatrics, body weight and age were the most common covariates reported to influence gentamicin CL, reflecting the importance of childhood growth and maturation on drug elimination. Which age-related factor was identified most likely depended on the population studied (proportion of premature babies) and study design. PNA and GA were commonly identified, reflecting the fact most studies included pre-term and term neonates. Few studies investigated postmenstrual age (PMA) or fat-free mass (FFM) as covariates. 74 In neonates and younger children CL CR and serum creatinine were often not identified as influencing factors on gentamicin CL, as they may not accurately reflect renal function in these populations. 75 Radiolabelled isotope methods can improve accuracy in estimating glomerular filtration rate in paediatrics and may be useful in certain clinical circumstances. 76 One large study involving 923 patients has suggested that maturation of glomerular filtration with age in premature neonates to young adults is best described using PMA and FFM. 77 Pre-term neonates had a larger volume of distribution than neonates, likely due to increased extracellular fluid relative to body weight in the former. 78 Large between-subject variability in CL and volume of distribution was observed in many studies in both adult and paediatric subjects, even after taking into account covariate influences. For successful exposure-based dose adjustment, between-occasion variability needs to be less than between-subject variability. 79 Indeed between-occasion variability estimates in one study in adults 24 appeared to be reasonable low 24 but were higher in another involving the critically ill. 33 Of the models developed, 55% still require further external validation to assess their predictive performance in new patient cohorts. Models with very high residual unexplained variability are unlikely to be useful for dosage prediction.
Only approximately half the population pharmacokinetic models developed for gentamicin have been applied in a Monte Carlo simulation study to compare different dosing regimens to see which one best achieves 'pre-defined' exposure targets. One limitation of most simulation studies to date is that they do not relate gentamicin dose or exposure with any clinical of microbiological outcome. It appears that only one study 80 has evaluated modelbased dosing recommendations that have been applied in practice to see what exposure or outcome was actually achieved. Monte Carlo simulations also rely on the predictive performance and generalizability of the models on which they are based.
Several studies have correlated efficacy of aminoglycosides with different exposure indices, most commonly C max /MIC !7-10 and AUC 24 /MIC !70-100. Most studies were performed in an adult population. Of note, different methods were used to determine exposure indexes such as C max (some measuring it at the end of the infusion, others 30 min or 1 h post-infusion). Significant correlation between C max and AUC 24 is highly likely, and therefore it is recommended to obtain data from different dosing regimens to distinguish between exposure indices. 81 These studies have some limitations. A large number of patients are required to sufficiently power the study. Variability in pharmacokinetic exposure among patients is not fully explained by currently observed patient characteristics. Further, different bacterial susceptibilities are not considered in these studies and there is a lack of existing clinical evidence on how exposure indices are associated with positive clinical outcomes.
It should be noted that the MIC is a threshold value that neglects any dynamic changes in bacterial growth and susceptibility. 81 In these studies the relationship between clinical and microbiological response is generally neglected, and difficult to account for (e.g. physiological changes during treatment and immune system activity may represent limiting factors in terms of determining which exposure index is better correlated to therapeutic effect). 81 Indeed the best exposure target may not be the same across patient populations with different pharmacokinetic characteristics and bacteria susceptibility. As aminoglycosides are often administered in combination with other antibiotics, results may be confounded by the antimicrobial actions of other agents. One study has highlighted the difficulties in applying pharmacokinetic/pharmacodynamic modelling at the level of the individual patient due to extreme pharmacokinetic variability and issues such as severity of illness. 63 Use of gentamicin is associated with significant nephrotoxicity and ototoxicity. Increased risk of toxicity has been related to a C min >2-3 mg/L. 10 No single standard upper limit to gentamicin trough concentrations to prevent toxicity is, however, used in practice. 82 In addition, it has been shown that routine measurement of gentamicin trough levels in neonates with low risk factors does not predict potential gentamicin toxicity. 82 The dosing regimen and duration of treatment have also been associated with toxicity. A once-daily dosing regimen of gentamicin has a lower rate of nephrotoxicity than multiple-daily dosing regimens in adults and paediatrics. 11, 83 Extended interval dosing has been suggested in pre-term neonates. 39, 56 Several studies have reported that the risk of aminoglycoside toxicity is highly associated with a longer duration of treatment. [84] [85] [86] Development of semi-mechanistic pharmacokinetic/ pharmacodynamic models of gentamicin is at an early stage [64] [65] [66] [67] [68] Review but is likely to be a more rational approach to describe drug-bacteria interactions than the MIC approach. 87 More recent inclusion of adaptive resistance processes into such models 64, 65 may help in the identification of dosing strategies that not only kill susceptible bacteria but also minimize the development of resistance. 64 These approaches have been successfully applied to select a dosing regimen for fusidic acid for FDA approval based on in vitro data and mathematical modelling. 88 A weakness of this approach, however, is that it relies on in vitro studies in which growth and killing behaviour might differ from in vivo situations (e.g. pharmacokinetics in target tissue or host immune response). All semi-mechanistic models developed for gentamicin to date predict bacteria regrowth upon drug removal as bacteria are not totally eradicated. However, in humans, immune activity can play an important role in killing lingering bacteria. Other limitations of these models are that they do not account for between-subject variability in pharmacodynamic responses, with the same exposure indices targeted in all patients and bacterial strains, and that they have not yet been tested in clinical practice. 81 Gentamicin is often given in combination with b-lactams. Quantitative time-course models that can predict the synergy effect of combined therapy are rare but are beginning to be developed. 89 Future studies on aminoglycoside-resistant strains are needed to assess the time-course of synergistic dual therapy against various different microorganisms.
Only one study to date has attempted to describe toxicity of aminoglycosides in a mechanistic fashion. 70 This study, however, is based on data from only eight subjects and used serum creatinine as a marker of renal function, which may not always be reliable as it is a belated indicator. 70 The relationship between drug exposure and ototoxicity is also poorly characterized, likely due to difficulties in its measurement and characterization. 90 The use of population pharmacokinetic/pharmacodynamic models and simulation tools represent a great step towards better personalization of gentamicin therapy; however, this field is still in its infancy. Future studies need to focus on evaluating combined therapy, characterizing the exposure-toxicity relationship of gentamicin and developing semi-mechanistic models that incorporate the influence of the immune response on the microbiological burden and combination therapy. Overall, as our understanding grows, dosing of gentamicin based on sound pharmacokinetic/ pharmacodynamic principles should be applied more commonly in clinical practice. Additional large prospective, real-time clinical studies are still needed to confirm the role of pharmacokinetic/ pharmacodynamic modelling in optimizing patient outcomes.
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